Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

745.77 -0.84 (-0.11%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	438,298
Open	754.55
Bid (Size)	735.00 (80)
Ask (Size)	755.00 (320)
Prev. Close	746.61
Today's Range	741.89 - 758.98
52wk Range	476.49 - 821.11
Shares Outstanding	91,779,465
Dividend Yield	0.50%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Is Eli Lilly's Weight Loss Empire in Trouble? ↗

March 13, 2026

It won't be easy to knock the company off its pedestal.

Via The Motley Fool

3 Profitable Stocks We Think Twice About

March 13, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...

Via StockStory

Performance

YTD	-3.9%	-3.9%
1 Month	-4.3%	-4.3%
3 Month	+0.6%	+0.6%
6 Month	+33.2%	+33.2%
1 Year	+9.6%	+9.6%

More News

In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making ↗

March 12, 2026

Via The Motley Fool

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

March 09, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Underrated Weight Loss Stocks to Buy Now ↗

March 08, 2026

Via The Motley Fool

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

March 05, 2026

Via StockStory

Regeneron Announces Investor Conference Presentation

March 05, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

2 Biotech Giants to Buy in 2026 ↗

March 05, 2026

Via The Motley Fool

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

February 27, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

February 26, 2026

From Society For Science

Via GlobeNewswire

2 Reasons Regeneron Stock Could Crush the Market for the Next 10 Years ↗

February 24, 2026

Via The Motley Fool

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

February 24, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗

February 21, 2026

Via The Motley Fool

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

February 19, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

Via MarketMinute

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

Via MarketMinute

1 Healthcare Stock Worth Your Attention and 2 Facing Challenges

February 12, 2026

Via StockStory

Regeneron Announces Investor Conference Presentations

February 11, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

February 10, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data

February 06, 2026

Via MarketMinute

Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗

February 05, 2026

Via The Motley Fool

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases

February 02, 2026

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?

Yes, Regeneron Pharmaceuticals is publicly traded.

What exchange does Regeneron Pharmaceuticals trade on?

Regeneron Pharmaceuticals trades on the Nasdaq Stock Market

What is the ticker symbol for Regeneron Pharmaceuticals?

The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market

What is the current price of Regeneron Pharmaceuticals?

The current price of Regeneron Pharmaceuticals is 745.77

When was Regeneron Pharmaceuticals last traded?

The last trade of Regeneron Pharmaceuticals was at 03/13/26 04:00 PM ET

What is the market capitalization of Regeneron Pharmaceuticals?

The market capitalization of Regeneron Pharmaceuticals is 68.45B

How many shares of Regeneron Pharmaceuticals are outstanding?

Regeneron Pharmaceuticals has 68B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.